eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
29 hedge funds and large institutions have $14M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 9 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
12% less funds holding
Funds holding: 33 → 29 (-4)
31% less capital invested
Capital invested by funds: $20.2M → $14M (-$6.19M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$110K |
| 2 |
SIMG
Sonora Investment Management Group
Tucson,
Arizona
|
+$86.8K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$15.7K |
| 4 |
EWA
EP Wealth Advisors
Torrance,
California
|
+$11.1K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$7.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$592K |
| 2 |
CG
Column Group
San Francisco,
California
|
-$197K |
| 3 |
Two Sigma Investments
New York
|
-$67.7K |
| 4 |
HF
HRT Financial
New York
|
-$25K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$23.9K |
EFTR Hedge Fund Activity: Q3 2023 in Review
29 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q3 2023, worth a combined $14M — down 31% from $20.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of EFTR and 5 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was Geode Capital Management, adding an estimated $110K. The largest seller was Renaissance Technologies, cutting an estimated $592K.
- 29 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q3 2023, down from 33 in Q2 2023.
- Funds reported $14M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q3 2023, down 31% quarter-over-quarter.
- 5 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q3 2023 and 9 closed out, a net change of -4 holders.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q3 2023 was Geode Capital Management, an estimated $110K added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q3 2023 was Renaissance Technologies, an estimated $592K sold.
Based on aggregated 13F filings for Q3 2023.